Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Insta360: Champion the Boldest, Craziest, Wildest of Ideas
Dec 07, 2023 03:35 PM
Chinese Enterprises are Ready to Tell Stories of Green China at COP28
Dec 02, 2023 12:28 AM
Consumer Electronics: ESG Emerging as a Hidden Highlight
Nov 30, 2023 10:11 PM